Advertisement
Canada markets open in 5 hours 37 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7311
    -0.0009 (-0.12%)
     

  • CRUDE OIL

    83.33
    -0.03 (-0.04%)
     

  • Bitcoin CAD

    91,135.30
    +542.73 (+0.60%)
     

  • CMC Crypto 200

    1,418.08
    -6.02 (-0.42%)
     

  • GOLD FUTURES

    2,334.70
    -7.40 (-0.32%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,716.50
    +109.75 (+0.62%)
     

  • VOLATILITY

    15.73
    +0.04 (+0.25%)
     

  • FTSE

    8,075.02
    +30.21 (+0.38%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6837
    +0.0001 (+0.01%)
     

Stocks in play: BioVaxys Technology Corp.

Baystreet.ca
·1 min read

Announced today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IND Type B review of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2. The FDA found the Chemistry, Manufacturing and Controls, and other elements of the clinical development program proposed by BioVaxys to be acceptable and provided guidance and feedback supportive of BioVaxys' clinical development plans for CoviDTH. In addition, the FDA indicated that animal toxicity studies for CoviDTH were not required and that the Company could start its clinical development program with a combined Phase I/II study. Based on this feedback, BioVaxys will begin preparation of an IND application to support a Phase I/II safety, dosing, and efficacy study. BioVaxys Technology Corp. shares C.BIOV are trading up 6 cents at $0.29.

Read: Levitee Labs Dedicated to Establishing Transformative Medicinal Wellness